263 related articles for article (PubMed ID: 25084153)
1. More severe manifestations and poorer short-term prognosis of ganglioside-associated Guillain-Barré syndrome in Northeast China.
Wu X; Wu W; Wang Z; Shen D; Pan W; Wang Y; Wu L; Wu X; Feng J; Liu K; Zhu J; Zhang HL
PLoS One; 2014; 9(8):e104074. PubMed ID: 25084153
[TBL] [Abstract][Full Text] [Related]
2. Elevated blood and cerebrospinal fluid glucose levels affect the severity and short-term prognosis of Guillain-Barré syndrome.
Gong Q; Liu S; Xiao Z; Fu X; Lu Z
Neurol Res; 2022 Feb; 44(2):121-127. PubMed ID: 34382919
[TBL] [Abstract][Full Text] [Related]
3. Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barré syndrome.
Press R; Matá S; Lolli F; Zhu J; Andersson T; Link H
J Neurol Sci; 2001 Sep; 190(1-2):41-7. PubMed ID: 11574105
[TBL] [Abstract][Full Text] [Related]
4. Anti-ganglioside antibodies profile in Guillain-Barré syndrome: Correlation with clinical features, electrophysiological pattern, and outcome.
Naik GS; Meena AK; Reddy BAK; Mridula RK; Jabeen SA; Borgohain R
Neurol India; 2017; 65(5):1001-1005. PubMed ID: 28879885
[TBL] [Abstract][Full Text] [Related]
5. Detection of anti-ganglioside antibodies in Guillain-Barré syndrome and its variants by the agglutination assay.
Alaedini A; Briani C; Wirguin I; Siciliano G; D'Avino C; Latov N
J Neurol Sci; 2002 Apr; 196(1-2):41-4. PubMed ID: 11959155
[TBL] [Abstract][Full Text] [Related]
6. Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain-Barré syndrome.
Hiraga A; Kuwabara S; Ogawara K; Misawa S; Kanesaka T; Koga M; Yuki N; Hattori T; Mori M
Neurology; 2005 Mar; 64(5):856-60. PubMed ID: 15753422
[TBL] [Abstract][Full Text] [Related]
7. [Antiganglioside autoantibody profiles in Guillain-Barré syndrome].
Caudie C; Vial C; Bancel J; Petiot P; Antoine JC; Gonnaud PM
Ann Biol Clin (Paris); 2002; 60(5):589-97. PubMed ID: 12368145
[TBL] [Abstract][Full Text] [Related]
8. Clinical, electrophysiological subtypes and antiganglioside antibodies in childhood Guillain-Barré syndrome.
Kannan MA; Ch RK; Jabeen SA; Mridula KR; Rao P; Borgohain R
Neurol India; 2011; 59(5):727-32. PubMed ID: 22019659
[TBL] [Abstract][Full Text] [Related]
9. GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barre syndrome.
Kaida K; Sonoo M; Ogawa G; Kamakura K; Ueda-Sada M; Arita M; Motoyoshi K; Kusunoki S
Neurology; 2008 Nov; 71(21):1683-90. PubMed ID: 19015484
[TBL] [Abstract][Full Text] [Related]
10. Association of antibodies to ganglioside complexes and conduction blocks in axonal Guillain-Barré syndrome presenting as acute motor conduction block neuropathy.
Créange A; Shahrizaila N; Salhi H; Lefaucheur JP; Yuki N
J Peripher Nerv Syst; 2014 Jun; 19(2):115-20. PubMed ID: 24750296
[TBL] [Abstract][Full Text] [Related]
11. Anti-ganglioside antibodies in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy in Chinese patients.
Fan C; Jin H; Hao H; Gao F; Sun Y; Lu Y; Liu Y; Lv P; Cui W; Teng Y; Huang Y
Muscle Nerve; 2017 Apr; 55(4):470-475. PubMed ID: 27464289
[TBL] [Abstract][Full Text] [Related]
12. Subtypes and Prognosis of Guillain-Barré Syndrome in Southwest China.
Zhang G; Li Q; Zhang R; Wei X; Wang J; Qin X
PLoS One; 2015; 10(7):e0133520. PubMed ID: 26200903
[TBL] [Abstract][Full Text] [Related]
13. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan.
Ogawara K; Kuwabara S; Mori M; Hattori T; Koga M; Yuki N
Ann Neurol; 2000 Oct; 48(4):624-31. PubMed ID: 11026446
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics of Intravenous Injection of Monosialotetrahexosyl Ganglioside Sodium-Related Guillain-Barre Syndrome.
Shi M; Zhu J; Deng H
Front Neurol; 2019; 10():225. PubMed ID: 30930839
[No Abstract] [Full Text] [Related]
15. Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: a Japanese-Italian collaborative study.
Sekiguchi Y; Uncini A; Yuki N; Misawa S; Notturno F; Nasu S; Kanai K; Noto Y; Fujimaki Y; Shibuya K; Ohmori S; Sato Y; Kuwabara S
J Neurol Neurosurg Psychiatry; 2012 Jan; 83(1):23-8. PubMed ID: 22010183
[TBL] [Abstract][Full Text] [Related]
16. Ganglioside complex antibodies in an Indian cohort of Guillain-Barré syndrome.
Wahatule R; Dutta D; Debnath M; Nagappa M; Mahadevan A; Sinha S; Sundaravadivel P; Rao U; Periyavan S; Binu VS; Rao S; Taly AB
Muscle Nerve; 2020 Dec; 62(6):728-734. PubMed ID: 32939766
[TBL] [Abstract][Full Text] [Related]
17. Ganglioside mimicry as a cause of Guillain-Barré syndrome.
Komagamine T; Yuki N
CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):391-400. PubMed ID: 16918391
[TBL] [Abstract][Full Text] [Related]
18. The immunobiology of Guillain-Barré syndromes.
Willison HJ
J Peripher Nerv Syst; 2005 Jun; 10(2):94-112. PubMed ID: 15958123
[TBL] [Abstract][Full Text] [Related]
19. An antibody to the GM1/GalNAc-GD1a complex correlates with development of pure motor Guillain-Barré syndrome with reversible conduction failure.
Ogawa G; Kaida K; Kuwahara M; Kimura F; Kamakura K; Kusunoki S
J Neuroimmunol; 2013 Jan; 254(1-2):141-5. PubMed ID: 23000056
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis of Guillain-Barré syndrome.
Hughes RA; Hadden RD; Gregson NA; Smith KJ
J Neuroimmunol; 1999 Dec; 100(1-2):74-97. PubMed ID: 10695718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
